OBJECTIVE: To measure the circulating levels of endocannabinoids and related molecules at fasting, after acute hyperinsulinemia and after weight loss in insulin sensitive vs. insulin resistant obese postmenopausal women. DESIGN AND METHODS: The sample consisted of 30 obese postmenopausal women (age: 58.9 ± 5.2 yrs; BMI: 32.9 ± 3.6 kg/m(2) ). Subjects underwent a 3-hour hyperinsulinaemic-euglycaemic clamp (HEC) (glucose disposal rate (M-value): 10.7 ± 3.3 mg min(-1) kg(-1) FFM) and 6-month weight loss intervention. Participants were classified as insulin sensitive obese (ISO) or insulin resistant obese (IRO) based on a predefined cutoff. Plasma levels of the endocannabinoids, anandamide (AEA), 2-arachidonoylglycerol (2-AG), and of the AEA-related compounds, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), were measured by liquid chromatography-mass spectrometry. RESULTS: IRO presented higher levels of 2-AG (P < 0.05) independently of the HEC and weight loss, whereas the HEC had an independent inhibitory effect on AEA, PEA, and OEA levels (P < 0.05) in both groups. Furthermore, there was an independent stimulatory effect of weight loss only on PEA levels in both groups (P < 0.05). CONCLUSIONS: This study is the first to show that higher circulating levels of the endocannabinoid 2-AG are found in IRO compared to ISO postmenopausal women, and that weight loss is associated with an increase in PEA, a PPAR-α ligand.
OBJECTIVE: To measure the circulating levels of endocannabinoids and related molecules at fasting, after acute hyperinsulinemia and after weight loss in insulin sensitive vs. insulin resistant obese postmenopausal women. DESIGN AND METHODS: The sample consisted of 30 obese postmenopausal women (age: 58.9 ± 5.2 yrs; BMI: 32.9 ± 3.6 kg/m(2) ). Subjects underwent a 3-hour hyperinsulinaemic-euglycaemic clamp (HEC) (glucose disposal rate (M-value): 10.7 ± 3.3 mg min(-1) kg(-1) FFM) and 6-month weight loss intervention. Participants were classified as insulin sensitive obese (ISO) or insulin resistant obese (IRO) based on a predefined cutoff. Plasma levels of the endocannabinoids, anandamide (AEA), 2-arachidonoylglycerol (2-AG), and of the AEA-related compounds, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), were measured by liquid chromatography-mass spectrometry. RESULTS: IRO presented higher levels of 2-AG (P < 0.05) independently of the HEC and weight loss, whereas the HEC had an independent inhibitory effect on AEA, PEA, and OEA levels (P < 0.05) in both groups. Furthermore, there was an independent stimulatory effect of weight loss only on PEA levels in both groups (P < 0.05). CONCLUSIONS: This study is the first to show that higher circulating levels of the endocannabinoid 2-AG are found in IRO compared to ISO postmenopausal women, and that weight loss is associated with an increase in PEA, a PPAR-α ligand.
Authors: James Nicholson; Syed Azim; Mario J Rebecchi; William Galbavy; Tian Feng; Ruth Reinsel; Sabeen Rizwan; Christopher J Fowler; Helene Benveniste; Martin Kaczocha Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240
Authors: Akhila Mallipedhi; Sarah L Prior; Gareth Dunseath; Richard M Bracken; Jonathan Barry; Scott Caplin; Nia Eyre; James Morgan; John N Baxter; Saoirse E O'Sullivan; Sarir Sarmad; David A Barrett; Stephen C Bain; Steve D Luzio; Jeffrey W Stephens Journal: J Diabetes Res Date: 2015-03-22 Impact factor: 4.011
Authors: Orison O Woolcott; Joyce M Richey; Morvarid Kabir; Robert H Chow; Malini S Iyer; Erlinda L Kirkman; Darko Stefanovski; Maya Lottati; Stella P Kim; L Nicole Harrison; Viorica Ionut; Dan Zheng; Isabel R Hsu; Karyn J Catalano; Jenny D Chiu; Heather Bradshaw; Qiang Wu; Cathryn M Kolka; Richard N Bergman Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240